Therapeutische Kombinationen mit Anti-FOLR1-Immunkonjugaten
EP4772183
8. Juli 2026
Anmelder: ImmunoGen, Inc. 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP4772183
- Anmeldetag
- 16. September 2016
- Veröffentlichung
- 8. Juli 2026
- Rechtsraum
- EP
- IPC
- A61K33/243
Abstract
Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
Anmelder
- Firma
- ImmunoGen, Inc.
- Land
- 🇺🇸 USA